STUB1 and Venous thrombosis: Analysis for CHIP mutations in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) clinical trial cohort (ClinicalTrials.gov NCT01327846), in which canakinumab (anti–IL-1β antibody) was administered to patients with prior myocardial infarction, revealed decreased subsequent major adverse cardiovascular events (MACEs) in subjects with TET2 mutations relative to those without CHIP (91).